These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38456894)

  • 1. Single-dose Tadalafil Reduces Opening Urethral Pressure: A Randomized, Double-blind, Placebo-controlled, Crossover Trial in Healthy Women.
    Christoffersen T; Riis T; Sonne DP; Klarskov N
    Int Urogynecol J; 2024 Mar; 35(3):723-729. PubMed ID: 38456894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single doses of citalopram and reboxetine on urethral pressure: A randomized, double-blind, placebo- and active-controlled three-period crossover study in healthy women.
    Christoffersen T; Kornholt J; Riis T; Sonne J; Sonne DP; Klarskov N
    Neurourol Urodyn; 2022 Aug; 41(6):1482-1488. PubMed ID: 35771361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of imipramine on urethral opening pressure: A randomized, double-blind, placebo-controlled crossover study in healthy women.
    Kornholt J; Sonne DP; Riis T; Sonne J; Klarskov N
    Neurourol Urodyn; 2019 Apr; 38(4):1076-1080. PubMed ID: 30843263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury.
    Takaoka EI; Kurobe M; Suzuki T; Shimizu N; Kwon J; Okada H; Yoshimura N; Chermansky CJ
    Neurourol Urodyn; 2020 Mar; 39(3):916-925. PubMed ID: 32040866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.
    Regadas RP; Reges R; Cerqueira JB; Sucupira DG; Josino IR; Nogueira EA; Jamacaru FV; de Moraes MO; Silva LF
    Int Urol Nephrol; 2013 Feb; 45(1):39-43. PubMed ID: 23108604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Roehrborn CG; Chapple C; Oelke M; Cox D; Esler A; Viktrup L
    J Urol; 2014 Apr; 191(4):1045-50. PubMed ID: 24445278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effect of tadalafil on lower urinary tract symptoms with erectile dysfunction].
    Ye XT; Huang H; Huang WP; Zhang FY
    Zhonghua Nan Ke Xue; 2019 Jun; 25(6):514-521. PubMed ID: 32223086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
    Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats.
    Izumi H; Kaiho Y; Miyazato M; Kawamorita N; Nakagawa H; Arai Y
    Int Urogynecol J; 2014 Dec; 25(12):1721-7. PubMed ID: 24988889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial.
    Nagasubramanian S; John NT; Antonisamy B; Mukha RP; Jeyachandra Berry CS; Kumar S; Devasia A; Kekre NS
    BJU Int; 2020 May; 125(5):718-724. PubMed ID: 32012409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of urethral closure function in women with stress urinary incontinence.
    Klarskov N; Scholfield D; Soma K; Darekar A; Mills I; Lose G
    J Urol; 2009 Jun; 181(6):2628-33; discussion 2633. PubMed ID: 19375093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
    Takeda M; Yokoyama O; Lee SW; Murakami M; Morisaki Y; Viktrup L
    Int J Urol; 2014 Jul; 21(7):670-5. PubMed ID: 24571205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.